|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 31/501 | (2006.01) |
| A61K 31/506 | (2006.01) | ||
| A61K 31/513 | (2006.01) | ||
| A61P 31/18 | (2006.01) | ||
| C07D 403/06 | (2006.01) | ||
| A61K 45/06 | (2006.01) |
| (11) | Number of the document | 3125894 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15774282.6 |
| Date of filing the European patent application | 2015-03-27 | |
| (97) | Date of publication of the European application | 2017-02-08 |
| (45) | Date of publication and mention of the grant of the patent | 2020-09-09 |
| (46) | Date of publication of the claims translation | 2020-12-10 |
| (86) | Number | PCT/US2015/022868 |
| Date | 2015-03-27 |
| (87) | Number | WO 2015/153304 |
| Date | 2015-10-08 |
| (30) | Number | Date | Country code |
| 201461973689 P | 2014-04-01 | US |
| (72) |
BURGEY, Christopher, S., US
FRITZEN, Jeffrey, F., US
BALSELLS, Jaume, US
PATEL, Mehul, US
|
| (73) |
Merck Sharp & Dohme LLC,
126 East Lincoln Avenue, Rahway, NJ 07065-0907,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | ŽIV atvirkštinės transkriptazės inhibitorių provaistai |
| PRODRUGS OF HIV REVERSE TRANSCRIPTASE INHIBITORS |
| Payment date | Validity (years) | Amount | |
| 2026-02-09 | 12 | 289.00 EUR |
| 2027-03-27 |